clinical trial · NCT04412863
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Chronic Hepatitis BVIR-2218pegylated interferon-alfa 2a
brief summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
started
Jul 3, 2020
primary completion
Mar 25, 2024
completion
Mar 25, 2024
last updated
Apr 16, 2026
official title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination With Pegylated Interferon Alpha-2a
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol